VFA
ECYT

Valeo Financial Advisors’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Valeo Financial Advisors’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,147
Closed -$5K – 1635
2017
Q4 		$5K Buy
+1,147
New +$5.46K ﹤0.01% 1045

Other funds holding ECYT

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Valeo Financial Advisors's ECYT Position: Q1 2018 in Review

Valeo Financial Advisors sold out of Endocyte, Inc. Common Stock (ECYT) in Q1 2018, closing a stake of 1,147 shares — an estimated $5K sold.

Valeo Financial Advisors first reported a position in ECYT in Q4 2017 and held it in 1 quarter. The position peaked at $5K in Q4 2017. 89 funds tracked by Wall St. Rank hold ECYT as of Q1 2018.

  • Valeo Financial Advisors reported no remaining Endocyte, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Valeo Financial Advisors sold 1,147 Endocyte, Inc. Common Stock shares in Q1 2018, an estimated $5K.
  • Valeo Financial Advisors first reported a position in Endocyte, Inc. Common Stock in Q4 2017 and held it in 1 quarter.
  • Valeo Financial Advisors's Endocyte, Inc. Common Stock position peaked at $5K in Q4 2017.
  • 89 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q1 2018.

Based on Valeo Financial Advisors's 13F filing for Q1 2018, filed 12 Apr 2018.